Systemically delivered measles virus-infected mesenchymal stem cells can evade host immunity to inhibit liver cancer growth

Journal of Hepatology

Volumn 59, Issue 5, 2013, Pages 999-1006

  Ong, Hooi Tin ^a   Federspiel, Mark J ^b   Guo, Chang M ^c   Ooi, London Lucien ^c   Russell, Stephen J ^b   Peng, Kah Whye ^b   Hui, Kam M ^a,d,e,f  

^a Humphrey Oei Institute of Cancer Research   (Singapore)

^b MAYO CLINIC   (United States)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

^d DUKE NUS MEDICAL SCHOOL   (Singapore)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^f INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

Author keywords

Hepatocellular carcinoma; Human neutralizing antibody; Mesenchymal stem cells as cell delivery vehicles; Oncolytic measles virus; Orthotopically implanted HCC tumor model; Systemic virotherapy

Indexed keywords

ALPHA FETOPROTEIN; IMMUNOGLOBULIN G; MEASLES ANTIBODY; NEUTRALIZING ANTIBODY; NUCLEOCAPSID PROTEIN; ONCOLYTIC VIRUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLUMINESCENCE; BONE MARROW; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SIZE; CANCER TRANSPLANTATION; CELL VIABILITY; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE IMAGING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE STATUS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LATENT PERIOD; LIVER CELL CARCINOMA; MEASLES VIRUS; MESENCHYMAL STEM CELL; MONOLAYER CULTURE; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; SCID MOUSE; TREATMENT OUTCOME; VIRUS IMMUNITY; VIRUS INFECTIVITY; VIRUS NUCLEOCAPSID; VIRUS REPLICATION;

HEPATOCELLULAR CARCINOMA; HUMAN NEUTRALIZING ANTIBODY; MESENCHYMAL STEM CELLS AS CELL DELIVERY VEHICLES; ONCOLYTIC MEASLES VIRUS; ORTHOTOPICALLY IMPLANTED HCC TUMOR MODEL; SYSTEMIC VIROTHERAPY;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BONE MARROW CELLS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; COCULTURE TECHNIQUES; DISEASE MODELS, ANIMAL; HETEROGRAFTS; HUMANS; IMMUNIZATION, PASSIVE; LIVER NEOPLASMS; MEASLES VIRUS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, SCID; ONCOLYTIC VIRUSES;

EID: 84885953332     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.07.010     Document Type: Article

References (28)

1. J. Ferlay, H.R. Shin, F. Bray, D. Forman, C. Mathers, and D.M. Parkin Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int J Cancer 127 2008 2893 2917
2. H.B. El-Serag, and K.L. Rudolph Hepatocellular carcinoma: epidemiology and molecular carcinogenesis Gastroenterology 132 2007 2557 2576
3. P.A. Farazi, and R.A. DePinho Hepatocellular carcinoma pathogenesis: from genes to environment Nat Rev Cancer 6 2006 674 687
4. J. Bruix, and M. Sherman Management of hepatocellular carcinoma: an update Hepatology 53 2011 1020 1022
5. P.A. Clavien, M. Lesurtel, P.M. Bossuyt, G.J. Gores, B. Langer, and A. Perrier Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report Lancet Oncol 13 2012 e11 e22
6. A. Zarrinpar, F. Kaldas, and R.W. Busuttil Liver transplantation for hepatocellular carcinoma: an update Hepatobiliary Pancreat Dis Int 10 2011 234 242
7. M. Burrel, M. Reig, A. Forner, M. Barrufet, C.R. de Lope, and S. Tremosini Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design J Hepatol 56 2012 1330 1335
8. J. Bruix, J.L. Raoul, M. Sherman, V. Mazzaferro, L. Bolondi, and A. Craxi Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial J Hepatol 57 2012 821 829
9. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, and J.F. Blanc Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
10. S.J. Russell, K.W. Peng, and J.C. Bell Oncolytic virotherapy Nat Biotechnol 30 2012 658 670
11. B. Blechacz, P.L. Splinter, S. Greiner, R. Myers, K.W. Peng, and M.J. Federspiel Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma Hepatology 44 2006 1465 1477
12. S.J. Russell, and K.W. Peng Measles virus for cancer therapy Curr Top Microbiol Immunol 330 2009 213 241
13. H.T. Ong, M.M. Timm, P.R. Greipp, T.E. Witzig, A. Dispenzieri, and S.J. Russell Oncolytic measles virus targets high CD46 expression on multiple myeloma cells Exp Hematol 34 2006 713 720
14. E. Galanis, L.C. Hartmann, W.A. Cliby, H.J. Long, P.P. Peethambaram, and B.A. Barrette Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer Cancer Res 70 2010 875 882
15. M. Dominici, K. Le Blanc, I. Mueller, I. Slaper-Cortenbach, F. Marini, and D. Krause Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement Cytotherapy 8 2006 315 317
16. M.F. Pittenger, A.M. Mackay, S.C. Beck, R.K. Jaiswal, R. Douglas, and J.D. Mosca Multilineage potential of adult human mesenchymal stem cells Science 284 1999 143 147
17. B.J. Jones, and S.J. McTaggart Immunosuppression by mesenchymal stromal cells: from culture to clinic Exp Hematol 36 2008 733 741
18. M.R. Reagan, and D.L. Kaplan Concise review: Mesenchymal stem cell tumor-homing: detection methods in disease model systems Stem Cells 29 2011 920 927
19. K.W. Peng, S. Facteau, T. Wegman, D. O'Kane, and S.J. Russell Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides Nat Med 8 2002 527 531
20. I.A. Ho, H.C. Toh, W.H. Ng, Y.L. Teo, C.M. Guo, and K.M. Hui Human bone marrow-derived mesenchymal stem cells suppress human glioma growth through inhibition of angiogenesis Stem Cells 31 2013 146 155
21. S. Ratnam, V. Gadag, R. West, J. Burris, E. Oates, and F. Stead Comparison of commercial enzyme immunoassay kits with plaque reduction neutralization test for detection of measles virus antibody J Clin Microbiol 33 1995 811 815
22. E.K. Mader, Y. Maeyama, Y. Lin, G.W. Butler, H.M. Russell, and E. Galanis Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model Clin Cancer Res 15 2009 7246 7255
23. S. Kidd, E. Spaeth, J.L. Dembinski, M. Dietrich, K. Watson, and A. Klopp Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging Stem Cells 27 2009 2614 2623
24. A. Munguia, T. Ota, T. Miest, and S.J. Russell Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth Gene Ther 15 2008 797 806
25. H.T. Ong, K. Hasegawa, A.B. Dietz, S.J. Russell, and K.W. Peng Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies Gene Ther 14 2007 324 333
26. K.W. Peng, A. Dogan, J. Vrana, C. Liu, H.T. Ong, and S. Kumar Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma Am J Hematol 84 2009 401 407
27. E.J. Read, A.M. Keenan, C.S. Carter, P.S. Yolles, and R.J. Davey In vivo traffic of indium-111-oxine labeled human lymphocytes collected by automated apheresis J Nucl Med 31 1990 999 1006
28. L.M. Esolen, B.J. Ward, T.R. Moench, and D.E. Griffin Infection of monocytes during measles J Infect Dis 168 1993 47 52